On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.

In the meantime, we continue with Impax’s announced commitments to clinical activities, including:

Clinical Activities
IND Phase 1 Phase 2 Phase 3 Approved
IPX229
Pediatric Migraine Ages 6-11
IPX203
Parkinson’s Disease Symptoms

Additional information regarding the pipeline at Impax Laboratories can be found at Press Releases.